NCT00574522

Brief Summary

The investigators are proposing that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of killer cells to fight and destroy the human immunodeficiency virus.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3

participants targeted

Target at below P25 for phase_1 hiv-infections

Timeline
Completed

Started Feb 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 12, 2007

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 17, 2007

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2008

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2009

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2009

Completed
Last Updated

August 17, 2009

Status Verified

August 1, 2009

Enrollment Period

1.5 years

First QC Date

December 12, 2007

Last Update Submit

August 14, 2009

Conditions

HIV Infections

Keywords

HIVAIDSRadiationFar infraredTreatmentAcquired Immunodeficiency SyndromeComplimentary therapies

Outcome Measures

Primary Outcomes (1)

  • The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 15μm wavelength) on HIV/AIDS.

    One year

Study Arms (1)

1

OTHER

Infrared Radiation, wavelength between 5 and 20 microns

Radiation: Far infrared

Interventions

Far infraredRADIATION

Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Year and above

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

HIV InfectionsAcquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus Diseases

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    PRINCIPAL INVESTIGATOR

  • Kwasi Donyina, Ph.D.

    GAAD Medical Research Institute Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 12, 2007

First Posted

December 17, 2007

Study Start

February 1, 2008

Primary Completion

August 1, 2009

Study Completion

November 1, 2009

Last Updated

August 17, 2009

Record last verified: 2009-08

Locations

CA(1)